Efinopegdutide Produces Strong Histologic Responses in Phase 2b MASH Study

Coverage, in order

1. 10h ago
   Patient Worthy obscure study

   Efinopegdutide Produces Strong Histologic Responses in Phase 2b MASH Study

   As reported on Business Wire, new data from Merck suggest that efinopegdutide, an investigational dual GLP-1/glucagon receptor agonist, may offer a promising new approach for treating metabolic dysfunction-associated steatohepatitis (MASH) accompanied by moderate-to-advanced liver fibrosis…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.